CIMG Inc., primarily engaged in the development and marketing of Maca-based consumer products in Asia, has experienced sustained net losses and liquidity challenges compounded by high supplier and customer concentration risks. Although revenue grew by 29.1% in FY2025, operating losses remain significant despite a 52.1% year-over-year improvement. Recently, the company expanded into the Chinese market through new agreements and acquisitions, presenting growth opportunities amidst regulatory complexities. Financially, the firm's low current ratio of 0.31 and history of negative operating cash flows underscore pressing near-term survival concerns. Successful innovation and effective management of regulatory and competitive barriers are critical for CIMG's trajectory.